Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 7/20 | 0.40 |
| ▸ | USP5 | P45974 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | UBE2M | P61081 | 2/20 | 0.38 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833133 | 0.93 | DRD2 (0.46) | DRD2CHRM4CCR2USP5TACR1 | |
| SCHEMBL4830071 | 0.90 | DRD2 (0.47) | DRD2CHRM4CCR2USP5TACR1 | |
| SCHEMBL4837219 | 0.89 | DRD2 (0.46) | DRD2CHRM4CCR2USP5TACR1 | |
| SCHEMBL4837566 | 0.86 | DRD2 (0.46) | DRD2CHRM4CCR2USP5CCR5 | |
| SCHEMBL4837310 | 0.85 | DRD2 (0.48) | DRD2CHRM4CCR2TACR1CCR5 | |
| SCHEMBL4835979 | 0.79 | DRD2 (0.48) | DRD2CHRM4CCR2USP5CCR5 | |
| SCHEMBL4830006 | 0.78 | HTR2A (0.54) | DRD2HTR2ADRD3 | |
| SCHEMBL4832880 | 0.77 | DRD2 (0.47) | DRD2CHRM4CCR2USP5GRM2 | |
| SCHEMBL4838989 | 0.76 | DRD2 (0.46) | DRD2CHRM4HTR2ADRD3 | |
| SCHEMBL4837124 | 0.76 | DRD2 (0.48) | DRD2CHRM4CCR2USP5GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384957-B2 | 3,4-dihydro-1H-isoquinolin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2008-06-10 | — | — | US | claimed |
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2005-03-31 | — | — | US | claimed |
| US-7384957-B2 | 3,4-dihydro-1H-isoquinolin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2008-06-10 | — | — | US | disclosed |
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | KCNJ2, KCNK2, KCNJ11 | DRD2 684/4885CHRM4 2171/4885CCR2 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.